Symphogen Names New Chief Financial Officer
COPENHAGEN, Denmark (15 September, 2016)
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Jesper Bramming has joined Symphogen as its new Chief Financial Officer, filling the position vacated by Martin Olin, M.Sc., EMBA, who was promoted to Chief Executive Officer and member of the Board of Directors.
Symphogen's founding CEO Kirsten Drejer steps down and becomes Executive Director
COPENHAGEN, Denmark (18 August, 2016)
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Kirsten Drejer, M.Sc., Ph. D., Co-founder, Chief Executive Officer and Director will transition from an executive operational role to an independent member of the Board of Directors. In parallel, Martin Olin, M.Sc., E*MBA, now Chief Financial Officer, has been promoted effective 1st September to Chief Executive Officer and member of the Board of Directors. Kirsten Drejer is proposed to be elected to the Board of Directors as an independent member and will, through a transition period, be a working Board member assisting Martin Olin.
Symphogen announces the appointment of Jeffrey H. Buchalter and Christoffer Søderberg as Non-Executive Directors
COPENHAGEN, Denmark (11 May, 2016)
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the appointment to the company's Board of Directors two new Non-Executive Directors: Mr. Jeffrey H. Buchalter and Mr. Christoffer Søderberg, effective 10 May 2016.
Symphogen Initiates Anti-MET Clinical Program And Presents Pre-Clinical Anti-MET Data at Annual AACR Meeting April 18th in New Orleans
Copenhagen, Denmark 12 April 2016
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today dosing of the first patient in its Sym015 program. Sym015 is an investigational mixture of two antibodies, targeting the MET receptor. The Phase 1 dose escalation study in patients with solid tumors will be followed by an expansion cohort in a subset patient population with a pre-identified gene signature. Two sites, START of San Antonio, Texas and The University of Texas MD Anderson Cancer Centre of Houston, Texas, will conduct the first-in-human study. Kirsten Drejer, Ph.D., Chief Executive Officer, said, "The initiation of this Phase 1 study represents a significant achievement by Symphogen in moving this promising program forward. It is our second proprietary clinical program, using antibody mixture targeting receptor tyrosine kinase, bringing Symphogen's total number of ongoing clinical studies to four. Importantly, we have retained all rights to the program." Anthony Tolcher, MD, FRCPC, FACP, President and co-founder of START, said, "We are enthusiastic about bringing this unique approach of an antibody mixture into the clinic. MET is a very exciting target for several solid tumors, and may have potential across multiple other tumor types. As such, Symphogen's novel antibody mixture may provide a unique opportunity to improve the life of patients with limited therapeutic options."
Symphogen to Present at JPMorgan Conference in San Francisco, CA
Copenhagen, Denmark – 12 January, 2016
Symphogen, a private biopharmaceutical Company developing recombinant antibody mixtures, announced today that Kirsten Drejer, Chief Executive Officer, will present an update on the Company at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 from 11:00 AM - 11.25 AM at San Francisco's Westin St. Francis Hotel in the Elizabethan D meeting room. The company announced earlier this month a strategic collaboration with Baxalta Incorporated, worth up to $1.6 billion plus royalties, to develop immuno-oncology candidate products.
Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology
BANNOCKBURN, Ill. and COPENHAGEN, Denmark, Jan. 4, 2016
Partnership aims to advance development of novel immune checkpoint therapies as Baxalta expands oncology leadership in orphan diseases. Symphogen to receive $175 million (€160 million) upfront, in addition to potential future milestone payments and royalties
Symphogen Receives Milestone Payment from Genentech for Initiation of Phase 1 Clinical Trial Candidate
Copenhagen, 2 December 2015.
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Genentech, a member of the Roche Group, has dosed for the first time in humans a clinical trial candidate containing a Symplex generated antibody conjugated to an undisclosed active agent.
Chief Executive Officer of Symphogen Kirsten Drejer, PhD stated: "The Genentech collaboration has allowed Symphogen to extend application of our integrated antibody discovery technologies to create value in therapeutic applications outside Symphogen's oncology focus and we are pleased to see this important compound advance into the clinic'.
Symphogen Announces Closing of a EUR 67.5 M Financing Subscribed by Existing Investors
Copenhagen, Denmark – 22 October, 2015
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the closing of a EUR 67.5 million convertible debt facility, secured from existing investors, led by Novo A/S and the Danish pension fund PKA. The proceeds will be used to progress the company's pipeline, specifically Sym004, a novel antibody mixture and its lead clinical program currently in a multi-center Phase 2b study in metastatic colorectal cancer patients with disease resistance or refractory to anti-EGFR antibody therapies. In addition, funds are earmarked to advance to the clinic both of the company's other fully owned assets, the pan-HER product candidate, Sym013, a mixture of six antibodies targeting each of EGFR, HER2 and HER3 and its MET product candidate, Sym015, a mixture of two antibodies targeting the MET receptor for treatment of patients with MET-amplified tumors. Symphogen is also deploying its proprietary mAb mix approach to its immuno-oncology research programs.
Symphogen's Antibody Mixtures Highlighted in Three Peer-Reviewed Journals
COPENHAGEN, Denmark, 28 May 2015:
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the publication in May 2015 of two papers with new clinical data for its lead anti-EGFR antibody mixture, Sym004, in the journals Cancer Discovery and in Cancer Chemotherapy and Pharmacology. In addition, a paper in Clinical Cancer Research described preclinical findings relating to the company's pan-HER product candidate, Sym013, a mixture of six antibodies targeting each of EGFR, HER2 and HER3 with a pair of synergistic antibodies. This body of evidence represents strong mechanistic validation for Symphogen's novel and pioneering antibody mixture approach to innovative oncology therapeutics. The clinical efficacy data published provided the basis for advancing Sym004 into a randomized Phase 2b study, currently ongoing in the USA and Europe. In the June issue of Cancer Discovery (Cancer Discovery; 5(6)), Dienstmann et al. report for the first time positive efficacy clinical findings for Sym004's study in patients with metastatic colorectal cancer (mCRC) and with acquired resistance to anti-EGFR antibody therapies.
Symphogen Regains Rights to Sym004 Announces Organizational Changes
COPENHAGEN, DENMARK 29 January 2015
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today several new corporate initiatives that reposition the company to focus on its proprietary pipeline of clinical oncology programs. The announcements address the regained rights to Sym004, a novel antibody mixture currently in a Phase 2b program, and a prioritization of the company's discovery activities in immuno-oncology.
Symphogen A/S Licenses the Selexis SUREtechnology Expression Platform and Cell Line
Geneva, Switzerland, December 9, 2014
Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development announced today that Selexis and Symphogen A/S have entered into a commercial license agreement and signed the continuation of their R&D license agreement. Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment of various cancers and infectious diseases.
Sym004 Advances into Two New Clinical Trials and Receives Milestone Payments
COPENHAGEN, Denmark (7 August 2014)
Symphogen to Report Preliminary Safety and Exploratory Efficacy Data from a Phase 1 Study of Sym004, Anti-EGFR Monoclonal Antibody Mixture at ASCO
COPENHAGEN, Denmark (29 May 2014)
Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today reported preliminary safety and exploratory efficacy data from a Phase 1 clinical study of Sym004, an investigational anti-EGFR monoclonal antibody mixture, administered biweekly, that will be presented in a poster at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 – June 3, 2014 in Chicago, IL. The poster, entitled, Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (29 pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment (abstract #3551) will be on view in the poster session on Gastrointestinal (Colorectal) Cancer (31 May 2014, 8:00 – 11:45 AM, McCormick Place Convention Center in Chicago, IL). Sym004 is a drug mixture of two mAbs targeting non-overlapping epitopes of EGFR which have been shown in pre-clinical studies to demonstrate synergistic inhibition of EGFR.
Symphogen Relocates to New Headquarters, Names Chief Manufacturing Officer
COPENHAGEN, Denmark (19 May 2014)
Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announced the relocation of its corporate headquarters in Lyngby, outside Copenhagen, Denmark to a 10.000 m2 (100,000 ft2) Facility in Ballerup, also a suburb of Copenhagen. Separately, Symphogen announced that Mads Laustsen was appointed to the newly created position of Chief Manufacturing Officer.
Gallus Enters Clinical cGMP Manufacturing Agreement with Symphogen
(St. Louis, Missouri – February 25, 2014)
Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization (CMO) has signed a manufacturing agreement with Symphogen, A/S (Symphogen), a private biopharmaceutical company developing recombinant monoclonal antibody (mAb) mixtures for the treatment of cancer.
Symphogen Presents Corporate Progress and Outlook at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, CA
COPENHAGEN, Denmark (14 January 2014)
Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today presented its achievements in 2013 and outlook for 2014 at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, California. The presentation was made by Kirsten Drejer, CEO.
Symphogen to Present at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, CA
COPENHAGEN, Denmark (10 January 2014)
Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announced that it will provide a corporate update at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, California, on Tuesday, January 14 at 10 am in Elizabethan C, at Westin St. Francis Hotel. Kirsten Drejer, CEO, will make the presentation. Kirsten Drejer, PhD., Symphogen's Chief Executive Officer, commented: "Symphogen has made significant progress across its pipeline for the treatment of cancer patients. Our highly qualified investors, who recognize the potential of Symphogen, continue their support and we are looking forward to expanding our capabilities in 2014".
Symphogen announces the appointment of Annika Espander Jansson as Non-Executive Director
COPENHAGEN, Denmark (20 December, 2013)
Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announces the appointment of Annika Espander Jansson as a Non-Executive Director of the Board, with effect from 19 December 2013. Annika has over twenty years' experience in the healthcare sector, both as a sell-side analyst and investor. She has a proven track record in strategic development of businesses and broad experience in managing operations in different segments of the financial markets.
Symphogen and Open Monoclonal Technology Announce Collaboration
Copenhagen, Denmark and Palo Alto, CA, October 15, 2013
Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, and Open Monoclonal Technology, Inc. (OMT), an innovator in transgenic animals for development of human therapeutic antibodies, today announced an alliance that provides Symphogen with unlimited access to OMT's OmniRat® and OmniMouse® platforms. Symphogen will use its proprietary B cell-based antibody identification technology, Symplex™, and access the diverse immune repertoires generated in OMT's transgenic animals to develop novel human therapeutic candidates.
Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration
COPENHAGEN, Denmark (26 June, 2013)
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it has received a milestone payment from Merck KGaA, Darmstadt, Germany, related to the successful achievement of specific development objectives for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).
Symphogen modtager Sym004 milepælsbetaling i samarbejdet med Merck KGaA
København, den 26. juni, 2013
Symphogen, et privat biofarmaceutisk selskab, der udvikler antistofblandinger til behandling af cancer, meddeler i dag, at de har modtaget milepælsbetaling fra Merck KGaA, Darmstadt, Tyskland, for opnåelsen af aftalte udviklingsmål for Sym004.
Symphogen Reports New Data on Anti-EGFR Monoclonal Antibody Mixture
Copenhagen, Denmark – June 2, 2013
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today at the 2013 Annual Meeting of the American Society of Clinical Oncology ( ASCO) the results of two proof-of-concept studies of SYM004, an anti-EGFR monoclonal antibody (mAb) mixture. Symphogen entered the antibody mixture into the clinic in 2010, and subsequently partnered with Merck KGaA, Darmstadt, Germany, in September 2012.
Symphogen to Report New Data on Anti-EGFR Monoclonal Antibody Mixture at ASCO
Copenhagen, Denmark – May 30, 2013
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today an oral presentation and a poster at the 2013 Annual Meeting of the American Society of Clinical Oncology ( ASCO) in Chicago, IL. Both cover the results of proof-of-concept studies of SYM004, an anti-EGFR monoclonal antibody (mAb) mixture. Symphogen entered the antibody mixture into the clinic in 2010, and subsequently partnered with Merck KGaA, Darmstadt, Germany, in September 2012.
Symphogen Præsenterer Nye Kliniske Data på Anti-EGFR Antistofblanding på ASCO
København – 30. maj 2013
Symphogen, et privat biofarmaceutisk selskab, der udvikler antistofblandinger meddeler i dag, at der både vil være en mundtlig præsentation og en poster session på det årlige "American Society of Clinical Oncology (ASCO)" i Chicago, IL, USA. Begge præsentationer vil vise kliniske resultater med Sym004, som er en anti-EGFR monoclonal antistof-blanding. Symphogen introducerede antistof blandingen i kliniske forsøg i 2010 og indgik i september 2012 et samarbejde med Merck KGaA, Darmstadt, Tyskland, om den videre udvikling af produktet.
Symphogen Expands Previous Private Equity Round, Reaching a Total of € 141 million (USD 185 million)
Copenhagen, Denmark – May 2, 2013
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it closed an expansion of its previously announced €100 million financing attaining a total of a €141 million placement of preferred stock to a group of existing investors. Novo A/S and PKA led the expansion with investments of €20 million each, while Danica Pension, participated with its pre-financing ownership share of the additional financing. The proceeds of the financing will be used to advance and expand Symphogen's proprietary oncology product pipeline of antibody mixture products addressing multiple targets in a single drug product.
Symphogen udvider kapitaltilførsel til et samlet provenu på mere end DKK 1 mia.
København, den 2. maj 2013
Symphogen, et privat biofarmaceutisk selskab, der udvikler antistofblandinger, meddeler i dag, at selskabet har gennemført en udvidelse af den tidligere annoncerede DKK 750 mio. finansieringsrunde til et samlet provenu på DKK 1,050 mia. fra en gruppe eksisterende investorer. Novo A/S og PKA investerer yderligere DKK 150 mio. hver, mens Danica Pension deltager med sin forholdsmæssige ejerandel. Provenuet vil blive anvendt til at videreudvikle og øge Symphogens patentbeskyttede cancer-pipeline.
Symphogen Presents New pan-HER data at Annual AACR Meeting
COPENHAGEN, Denmark, April 10. 2013
Symphogen today at the Annual Meeting of the American Association for Cancer Research in Washington DC, presented new preclinical data suggesting that a mixture of antibodies, known as pan-HER, that simultaneously inhibits EGFR, HER2 and HER3, is superior to existing targeted therapies in dealing with both primary and acquired resistance due to HER family dependency. At the poster session on Immune Therapeutics and Monoclonal Antibodies, Johan Lantto, Ph.D., Principal Scientist and Project Leader, concluded that pan-HER represents a novel strategy to address tumor heterogeneity and tumor plasticity (Abstract # 4751/20).
Symphogen to Present at 31st Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, 3 January, 2013
Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment diseases such as cancer or infectious and autoimmune diseases, today announced that the company is scheduled to present next Monday, 7 January at 8 am PT in the Elizabethan C/D Ballroom of the Westin St. Francis Hotel at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
COPENHAGEN, DENMARK – 6 September 2012
A novel investigational antibody mixture targeting the epidermal growth factor receptor (EGFR)
Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR). Sym004 is currently being evaluated in a Phase I/II trial for the treatment of patients with advanced KRAS wild-type metastatic colorectal cancer (mCRC) who have previously progressed on treatment with standard chemotherapy and a marketed anti-EGFR monoclonal antibody. In addition, a single-arm, open-label Phase II trial in patients with squamous cell carcinoma of the head and neck (SCCHN) who have failed anti-EGFR–based therapy is currently ongoing.
Symphogen Enters Project Supported by the Danish National Advanced Technology Foundation: Immune Antibody Repertoires in Microdroplets
Copenhagen, September 3, 2012
The technology project, which is supported by the Danish National Advanced Technology Foundation, involves an interdisciplinary approach combining cutting edge science from the fields of genomics, bioinformatics, nanotechnology and drug development. The goal is to provide improved therapeutic antibodies for the treatment of cancer and to identify new prognostic biomarkers for allergy vaccines for the benefit of cancer patients and chronically ill allergy patients.
Symphogen Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ITP in Blood
COPENHAGEN, Denmark, 22 August 2012
The hematology journal BLOOD has published a full-length article describing final Phase 2 data for Symphogen's rozrolimupab, a novel human recombinant mixture of 25 antibodies which all are manufactured simultaneously from a single batch. The data demonstrates rozrolimupab's favorable safety profile and its induction of a rapid increase in platelet counts in patients with Primary Immune Thrombocytopenia Purpura (ITP). Professor Tadeusz Robak, MD, University of Lodz, Poland, is the first author of the article entitled "Rozrolimupab, A Mixture of 25 Recombinant Human Monoclonal RhD Antibodies, in the treatment of Primary Immune Thrombocytopenia" which has been prepublished in First Edition of Blood and can be viewed on Blood Online at http://bloodjournal.hematologylibrary.org/content/early/recent.
Symphogen Names Martin Olin Chief Financial Officer and Receives 2nd Tranche from €100 Million 2011 Financing
Copenhagen, Denmark – 2 April 2012
Symphogen announced today the appointment of Martin Olin to the position of Chief Financial Officer. Symphogen also said it received the second of three tranches of capital specified in its €100 million 2011 financing.
Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH
COPENHAGEN, Denmark, 12 December 2011
Symphogen today presented final Phase 2 data demonstrating that its recombinant polyclonal antibody drug candidate rozrolimupab exhibited a favorable safety profile and induced a rapid increase in blood platelets in patients with Immune Thrombocytopenia Purpura (ITP). The trial demonstrated that at 300µg/kg, the best dose, 8 of 13 (62%) of patients responded at day 7. Median time to response was 59 hours (approximately 2.5 days) and the median duration of response was 14 days. The Phase 2 study was an open-label, multi-center clinical trial evaluating the efficacy, safety, and tolerability of rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized ITP patients.
Symphogen Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck Cancer
COPENHAGEN, Denmark (August 23, 2011)
Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). In June 2011 Symphogen completed the enrollment of patients in another study to evaluate the safety, efficacy and PK of Sym004 in patients with advanced metastatic colorectal cancer (mCRC) and wild-type KRAS.
Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology Association
Copenhagen, Denmark – June 10, 2011
Symphogen announced today preliminary data from a phase 2 clinical trial with rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP). The study showed rozrolimupab is well tolerated with no unexpected toxicities and shows preliminary signs of clinical and biological activity by decreasing haemoglobin values.
Symphogen to Present Rozrolimupab (SYM001) Data at European Hematology Association Meeting
COPENHAGEN, Denmark, 2 June 2011
Symphogen announced today that Phase 2 data will be presented from an open-label, multi-center clinical trial evaluating the safety and tolerability of rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP) at the 16th Congress of the European Hematology Association meeting (http://eha.eurocongres.com/16th/) in London, UK on June 10 from 5:45 to 7:00 PM. Preliminary results will be presented in a poster entitled "Phase II results of the first-in-class anti-RhD antibody mixture, rozrolimupab in primary immune thrombocytopenia (ITP)" by professor Tadeusz Robak of University of Lodz, Poland at the Immune Thrombocytopenia Poster Session.
Symphogen to Present Data from the First Clinical Trial with Sym004 at ASCO
Copenhagen, Denmark – 1 June, 2011
Symphogen announced today that the company will present preliminary Phase 1 data evaluating the company's lead cancer compound, Sym004, at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago. At the General Poster Session on June 6 from 8 AM to 12 PM, preliminary results from the ongoing Phase 1 open-label, multi-center dose escalation trial evaluating the safety and tolerability of multiple doses of Sym004 will be provided. The poster is entitled "Phase I Trial Of The First-In-Class EGFR mAb Mixture, Sym004, In Patients With Refractory Advanced Solid Tumors" by Dr. Rodrigo Dienstmann of the Vall d'Hebron University Hospital, Barcelona, Spain.
SympressT Platform to be presented at ESACT Conference 17 May 2011
Copenhagen, Denmark – May 11, 2011
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS™ manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology (ESACT) conference in Vienna on May 17, 2011. Additionally, a paper published online April 25, 2011 in BIOTECHNOLOGY and BIOENGINEERING describes Symphogen's proprietary Sympress™ manufacturing, release and characterization strategy for rozrolimupab/Sym001, a recombinant polyclonal antibody product in Phase 2 clinical trials.
Symphogen Welcomes Four New Board Members
Copenhagen, Denmark – April 19, 2011
Symphogen, announced today that four new members have been elected to the company's Board of Directors: Dr. Sam Broder, Dr. John B. Landis, Mr. Jeppe Christiansen and Tom Bork Petersen, Esq. Symphogen also said that three longstanding directors will be leaving the board: Dr. Martin Edwards, Dr. Laurence Jay Korn and Dr. Jack Johansen.
Symphogen names new Chief Scientific/Medical and Business Officers
Copenhagen, Denmark – April 15, 2011
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced today the completion of its senior management team with the addition of a new Chief Scientific/Medical Officer, Ivan D. Horak, M.D.,FACP and a new Chief Business Officer, Gayle M Mills.
Symphogen Receives US Patent on Lead Cancer Compound Sym004
Paris, France – March 7
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics. The United States Patent and Trademark Office on February 15, 2011 issued to the company U.S. Patent No. 7,887,805, titled "Recombinant anti-epidermal growth factor receptor antibody compositions." The US patent provides protection through 2028. Patent applications are pending in additional countries.
SYMPHOGEN Raises €100 Million in Private Equity Round
Copenhagen, Denmark – January 6, 2011
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced today that it closed a €100 million placement of Preferred Stock to a group of investors. Novo A/S led the round. Essex Woodlands Fund VIII joined previous investments made by Funds V and VI. Together, Novo A/S and Essex Woodlands are contributing 70% of the investment, which is scheduled to occur over three equal tranches. The Danish Pension Fund PKA also joined as a new investor. The € 100 million raised is the largest ever financing for a private European biotech company.Symphogen intends to use the proceeds to accelerate advancement of its lead clinical oncology product Sym004 as well as its other clinical and preclinical oncology opportunities both for proprietary pursuit and partnering.
Swedish Orphan Biovitrum returns development rights to Sym001 to Symphogen
Stockholm, Sweden - December 30, 2010
Swedish Orphan Biovitrum (STO:SOBI) today announced that it has returned full development rights to Symphogen, co-developer of Sym001, for ITP (Immune Thrombocytopenic Purpura) treatment and for HDN (Hemolytic Disease in Newborn) prophylaxis, for strategic reasons.
Symphogen Receives Milestone Payment from Genentech for Antibody Therapeutic Against Infectious Disease Target
COPENHAGEN, Denmark and PRINCETON, New Jersey (November 30, 2010)
Symphogen A/S announced today that it has received an undisclosed milestone payment related to an antibody therapeutic in development under its ongoing collaboration with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). The collaboration covers antibody therapeutics against three infectious disease organisms.
Symphogen and Swedish Orphan Biovitrum receive U.S. orphan drug designation for Rozrolimupab in ITP
COPENHAGEN, Denmark and Stockholm, Sweden – October 6, 2010
Symphogen and Swedish Orphan Biovitrum (STO:SOBI) today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to rozrolimupab (Sym001) for the treatment of primary Immune Thrombocytopenia (ITP).
Symphogen Announces Publication of Data on the Manufacture of Polyclonal Antibodies Developed Using Sympress™ Technology
COPENHAGEN, Denmark and PRINCETON, New Jersey (September 16, 2010)
Symphogen A/S announced today the publication of data in the September 1, 2010 edition of the journal Analytical Chemistry (Persson P. et al, volume 82, issue 17, pp. 7274-7282) demonstrating that a new method based on mass spectrometry is capable of determining the relative distribution of antibodies manufactured through the Company's proprietary Sympress™ technology. The results indicate that mass spectrometry provides an accurate method of quantifying all 25 antibodies in Sym001, Symphogen's lead recombinant polyclonal antibody (rpAb) product for the treatment of idiopathic thrombocytopenic purpura (ITP) and the prevention of hemolytic disease in newborns (HDN).
Symphogen Issued United States Patent Covering Symplex™ Technology for Antibody Discovery
COPENHAGEN, Denmark and PRINCETON, New Jersey 13 July, 2010)
Symphogen A/S announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 7,749,697, titled "Method for linking sequences of interest." The patent broadly covers Symphogen's Symplex™ technology, a novel PCR-based process for identifying and isolating target-specific high affinity antibodies, the starting point for discovery and development of antibody drugs customized to a particular therapeutic application. The technology allows efficient high-throughput isolation of antibodies maintaining the natural high binding affinity and specificity of the original donor antibodies. In addition to the United States patent, patents on the Symplex™ technology have been granted in numerous territories worldwide, including a European patent covering 27 countries.
Symphogen Announces Publication in Molecular Biotechnology of Sympress ™ II Production System Allowing Single-Batch Recombinant Polyclonal Antibody Manufacturing
COPENHAGEN, Denmark and PRINCETON, New Jersey (April 26, 2010)
Symphogen A/S today announced the publication of data in the March 20, 2010 online edition of Molecular Biotechnology by Nielsen LS et al. [epub ahead of print] demonstrating the ability of its Sympress II technology to enable cost-effective production of recombinant polyclonal antibodies (rpAb) and antibody mixtures with batch-to-batch consistency that the Company believes could supply drug product for large indications such as cancer and infectious disease. The Sympress II results demonstrated single-batch production of compositions with as many as six antibodies with a controlled and appropriate distribution in the final product.
Symphogen Announces Initiation of Phase 1/2 Trial of Sym004 in Patients with Advanced Solid Tumors in the US
COPENHAGEN, Denmark and PRINCETON, New Jersey (April 1, 2010)
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies targeting different nonoverlapping EGFR epitopes.
Symphogen Publishes Pre-Clinical Data in Cancer Research Demonstrating Superior Efficacy of Anti–EGFR Monoclonal Antibody Combination Sym004
COPENHAGEN, Denmark and PRINCETON, New Jersey (January 11, 2010)
Symphogen A/S today announced the publication of encouraging data for Sym004 in the on-line edition of Cancer Research (January 15, 2010; 70(2)). The data showed that Sym004 provided synergistic inhibitory effects against cancer cell lines of different tissue origin in vitro and in vivo.
Symphogen Opens US Operations in Princeton, New Jersey
COPENHAGEN, Denmark and PRINCETON, NJ (November 3, 2009)
Symphogen A/S today announced the opening of its United States headquarters in Princeton, New Jersey. Adriann Sax, Symphogen's recently appointed Chief Business Officer, will head the Company's US business which will operate as Symphogen, Inc., a wholly-owned subsidiary of Symphogen A/S.
Symphogen Appoints Jørgen Petersen as Chief Development Officer
COPENHAGEN, Denmark (October 20, 2009)
Symphogen A/S today announced that Jørgen Petersen, M.D., DMSc, has joined the company's executive management team as Chief Development Officer. Dr. Petersen comes to Symphogen from Genmab A/S.
Symphogen Appoints Adriann Sax Chief Business Officer
COPENHAGEN, Denmark (August 17, 2009)
Symphogen A/S today announced that Adriann Sax has joined the company's management team as Chief Business Officer.
Symphogen and Origen Collaborate to Produce Transgenic Chicken for generation of Fully Human Antibody Therapeutics
COPENHAGEN, Denmark and EMERYVILLE, CA (March 6, 2009)
Symphogen A/S and Origen Therapeutics today announced a strategic collaboration to develop a transgenic chicken capable of producing human antibodies against a wide variety of disease targets. Origen will use its avian transgenic technology to develop transgenic chickens, which can be immunized with any disease target of interest, including diseases such as cancer, and autoimmunity. Symphogen will apply its antibody discovery and expression platforms to create novel recombinant fully human monoclonal and polyclonal antibody therapeutics against such targets. Both companies plan to employ the jointly developed transgenic technology to produce novel antibody therapeutics.
Symphogen secures € 33 million financing to support clinical development of antibody products
COPENHAGEN, Denmark. February 4, 2009.
Symphogen A/S today announced the closing of a € 33 million (approximately U.S. $44 million) financing. Existing investors participated in the round, which was led by Essex Woodlands Health Ventures. The financing will be used to mature the company's product pipeline of antibody therapeutics, particularly within the field of oncology.
Symphogen acquires Receptor BioLogix's technology
COPENHAGEN, Denmark and PALO ALTO, Calif., U.S. January 29, 2009.
Symphogen Adds Receptor's Pan-HER Ligand Trap Technology to Diversify Recombinant Polyclonal Antibody Portfolio - both Technology Platforms Explicitly Target Disease Complexity
Symphogen A/S and Receptor BioLogix, Inc, (Receptor) announced today that Symphogen has acquired the technology and programs of Receptor BioLogix. Symphogen is a leader in developing recombinant polyclonal antibodies, a new class of biopharmaceuticals, and Receptor BioLogix is a pioneer in developing pan-HER ligand traps to treat cancer and other diseases. Both companies are privately owned.
Symphogen and Meiji Seika Kaisha LTD. Achieve milestone in discovery collaboration for recombinant polyclonal antibody, SYM006
COPENHAGEN, Denmark and TOKYO, Japan – December 4, 2008.
Symphogen A/S and Meiji Seika Kaisha Ltd. (TSE: 2202) announced today the advancement of their collaboration for the discovery, development and commercialization of a recombinant polyclonal antibody therapeutic, Sym006, that targets an undisclosed bacterial pathogen. The companies, who initiated the collaboration in December 2006, are moving the program into preclinical development. As a result, Symphogen will receive a milestone payment from Meiji under the terms of the agreement. "We are pleased to move our Sym006 partnership with Meiji forward into preclinical development, after achieving proof-of-concept for our recombinant polyclonal antibody therapeutic in relevant animal models," said Kirsten Drejer, Ph.D., Chief Executive Officer of Symphogen A/S. "This is an important validation of our antibody discovery technology, Symplex™, which Meiji used to identify a broad representation of antibodies from naturally immune human donors. Meiji will continue development of Sym006 using Symphogen's Sympress™ technology for the manufacture and characterization of this recombinant polyclonal antibody product."
Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers
Copenhagen, Denmark – December 1, 2008.
Results will be discussed at the European Antibody Congress in Geneva, December 2 and at the IBC's International Conference on Antibody Engineering in San Diego, December 11.
Symphogen A/S today announced that John Haurum, Chief Scientific Officer and Michael Kragh, Director of Antibody Pharmacology will present positive preclinical data on the Company's Sym004 program for the discovery and development of antibodies against EGF receptor (EGFR)-positive cancers. The data will be presented at two upcoming conferences: the 4th Annual European Antibody Congress in Geneva on December 2 and at the IBC's 19th Annual International Conference on Antibody Engineering in San Diego on December 11, 2008.
Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project
STOCKHOLM, Sweden and COPENHAGEN, Denmark – November 20, 2008.
Biovitrum AB (publ) (STO:BVT) and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for future prevention of Hemolytic Disease of the Newborn (HDN) that can occur in RhD-negative mothers carrying a RhD-positive fetus. This can lead to an immune reaction causing destruction of the red blood cells in the newborn, which may give rise to severe anemia, jaundice, and even cause heart failure and fatality.
Symphogen-Biovitrum Phase II Clinical Trial Initiated
COPENHAGEN, Denmark and STOCKHOLM, Sweden– July 16, 2008.
Symphogen A/S and Biovitrum AB (publ) (STO:BVT) today announced the recruitment of the first patient into a Phase II clinical trial, initiated in June, to evaluate the safety and efficacy, and explore the dose range of Sym001 in Idiopathic Thrombocytopenic Purpura (ITP) patients. Sym001 is a recombinant, polyclonal anti-Rhesus D antibody product candidate. Symphogen and Biovitrum are jointly developing Sym001 under a 50/50 co-development and commercialization agreement announced in February 2006.
Symphogen Enters into Strategic Collaboration with Genentech for Antibody Therapeutics
COPENHAGEN, Denmark – June 10, 2008.
Symphogen A/S announced today that it has entered into a global strategic collaboration with Genentech, Inc. for antibody therapeutics against three undisclosed infectious disease targets.
Biovitrum and Symphogen Initiate a Second Clinical Study with a Novel Treatment of Hemolytic Diseases
PRESS RELEASE, April 15, 2008
STOCKHOLM, Sweden and COPENHAGEN, Denmark – Biovitrum AB (publ) (Ticker: STO:BVT) and Symphogen A/S today announced the initiation of a clinical proof of mechanism study to demonstrate the ability of Sym001 (RhD polyclonal antibody) to clear RhD-positive red blood cells from the circulation of RhD-negative healthy volunteers. Clearance of red blood cells by RhD antibodies is an important treatment in preventing hemolytic disease in RhD-positive newborns with RhD-negative mothers.
Symphogen issued patent covering Symplex™ technology for antibody discovery
COPENHAGEN, Denmark – March 5, 2008.
Symphogen A/S announced today that the European Patent Office granted the Company European Patent number 1 669 912 B1, which describes a high-throughput method for isolating fully human, antigen-specific antibodies directly from human donors, and other related methods. The patent covers Symplex™, Symphogen's proprietary process for discovering antibodies with diversity and specificity customized to a particular therapeutic application. The granted European patent is effective in 33 countries across Europe. Symphogen has additional pending applications from this patent in numerous countries across the world.
Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinant Polyclonal Antibody to Enter Clinical Evaluation
COPENHAGEN, Denmark and STOCKHOLM, Sweden - March 12, 2007.
Symphogen and Biovitrum today announced the initiation of a Phase 1 clinical trial to test the safety, pharmacokinetics and pharmacodynamics of Sym001 (Anti-RhD) in healthy volunteers. Sym001 is a recombinant, polyclonal antibody product candidate, comprised of 25 different anti-Rhesus D antibodies. Sym001 is in development for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and for the prevention of Hemolytic Disease of the Newborn (HDN). Symphogen and Biovitrum are jointly developing Sym001 under a co-development and commercialization agreement announced in February 2006.
Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody
PRESS RELEASE, February 6, 2008
Biovitrum and Symphogen are developing a recombinant, polyclonal antibody (Sym001) for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and prophylaxis of rhesus hemolytic disease of the newborn. The phase I clinical trial was initiated in March 2007 and the results from the study show that Sym001 is safe and well tolerated.
Biovitrum og Symphogen har færdiggjort succesfyldt fase I klinisk forsøg med et rekombinant polyklonalt antistof
PRESSEMEDDELELSE, 6. februar, 2008
Biovitrum og Symphogen udvikler en lægemiddelkandidat baseret på rekombinante polyklonale antistoffer (Sym001) til behandling af autoimmun trombocytopenisk purpura og forebyggelse af Rhesus-betinget hæmolytisk sygdom hos nyfødte. Det kliniske fase I forsøg blev indledt i marts 2007, og resultaterne viser, at lægemiddelkandidaten er sikker og tolereres godt af den menneskelige organisme.
Symphogen IBC Sym003 Press release
Copenhagen, Denmark – December 4, 2007.
Symphogen A/S today announced that John Haurum, Chief Scientific Officer, will present positive preclinical data on the Company's Sym003 program against respiratory syncytial virus (RSV) at IBC's 18th Annual International Conference on Antibody Engineering in San Diego. The presentation will take place on December 5, 2007. Sym003 is a recombinant human polyclonal antibody composition that is being developed to combat RSV infection.
Symphogen A/S kåret som Danmarks bedste biotekvirksomhed
Symphogen A/S awarded Best Danish Biotech Company 2007
Symphogen A/S was awarded Entrepreneur of the Year 2007 in the category Biotech and consequently can describe themselves as Denmark's best biotech company. The company has just been elected the winner of the Biotech category in Ernst & Young's Entrepreneur of the Year 2007 competition. In the final also Astion Pharma A/S and Rheoscience A/S were nominated.
Symphogen appoints Ian Nicholson to Board of Directors
COPENHAGEN, Denmark – May 16, 2007.
Symphogen A/S announced today that Ian Nicholson, B.Sc., MBA, has joined its Board of Directors. Mr. Nicholson is currently Chief Executive Officer of Chroma Therapeutics Limited and brings to Symphogen 25 years of experience in biotechnology business development, sales, and marketing.
Symphogen styrker bestyrelse
KØBENHAVN, 16. maj 2007.
Den danske biotekvirksomhed Symphogen A/S meddeler i dag, at Ian Nicholson, B.Sc., MBA, indtræder i virksomhedens bestyrelse. Nicholson er administrerende direktør i Chroma Therapeutics Limited og medbringer over 25 års erfaring inden for biotek, forretningsudvikling, salg og marketing. I sin nuværende stilling i Chroma Therapeutics har Nicholson det overordnede ansvar for forskning, klinisk udvikling, økonomi og forretningsudvikling. Nicholson er arkitekten bag Chromas succesfulde finansieringsrunder og stod bl.a. bag den største private biotekfinansiering i Europa i første halvdel af 2006.
Symphogen Granted European Patent Covering Use of Polyclonal Antibodies for Allergy Indications
COPENHAGEN, Denmark – May 7, 2007.
Symphogen A/S announced today that it has been granted European Patent number 1,283,720 B1 for use of polyclonal antibodies in allergy indications. The patent broadly covers the manufacture and use of allergen-specific polyclonal antibodies for the prevention and treatment of allergic reactions. Symphogen holds equivalent patents in the United States and India and has pending patent applications in additional countries.
Symphogen og Biovitrum indleder kliniske studier af ny type lægemiddel
KØBENHAVN, Danmark, og STOCKHOLM, Sverige – 12. marts 2007.
Biotekvirksomheden Symphogen A/S meddeler, at selskabet i samarbejde med svenske Biovitrum for første gang nogensinde indleder kliniske undersøgelser af rekombinante polyklonale antistoffer i mennesker. Rekombinante polyklonale antistoffer er en ny type lægemidler, der efterligner vores immunsystems naturlige måde at bekæmpe sygdomme på. Symphogens mest fremskredne produkt, Sym001, der består af 25 forskellige antistoffer, vil blive anvendt til behandling af den sjældne blødningssygdom ITP og til forebyggelse af spædbarnssygdommen HDN. Symphogen og Biovitrum indgik sidste år en samarbejdsaftale om udvikling og markedsføring af Sym001.
Symphogen receives 5 Million Euro investment from Gilde Healthcare Partners
COPENHAGEN, Denmark – January 31, 2007.
Symphogen announced today that it has raised 5 million Euro (6.5 million USD) from Dutch venture capital fund Gilde Healthcare Partners. This investment is an addition to Symphogen's last financing round and brings the company's total amount of money raised to 85 million USD.
Symphogen og Meiji indgår samarbejde
København, Danmark, og Tokyo, Japan – 11. december, 2006.
Den danske biotekvirksomhed Symphogen A/S og den japanske medicinalvirksomhed Meiji Seika Kaisha Ltd. har indgået samarbejde om at anvende Symphogens teknologiplatform til at udvikle, producere og markedsføre rekombinante polyklonale antistoffer mod en ikke oplyst bakteriegruppe.
Symphogen and Meiji Kaisha enter agreement for recombinant polyclonal antibody product
COPENHAGEN, Denmark and TOKYO, Japan – December 11, 2006.
Symphogen A/S and Meiji Seika Kaisha Ltd. (TSE: 2202) announced today that they have entered into a research, development and commercialization agreement that utilizes Symphogen's proprietary antibody discovery and manufacturing technologies to develop a fully human recombinant polyclonal antibody (pAb) product candidate that targets a non-disclosed bacterial pathogen.
Symphogen A/S styrker klinisk udvikling
København, Danmark – 7. november, 2006.
Den danske biotekvirksomhed Symphogen A/S har ansat Christian Meyer, M.D., Ph.D, som Vice President of Clinical Development. Samtidig er Senior Vice President Henrik Rasmussen, M.D., Ph.D., fra Nabi Biopharmaceuticals tiltrådt som medlem af Symphogens internationale team af medicinske rådgivere, Medical Advisory Board.
Symphogen appoints Christian Meyer Vice President of Clinical Development and Dr. Henrik Rasmussen to Medical Advisory Board
COPENHAGEN, Denmark – November 7, 2006.
Symphogen announced today that Christian Meyer, M.D., Ph.D., has been appointed Vice President of Clinical Development. In this role, Dr. Meyer will lead Symphogen's clinical development activities for its portfolio of recombinant polyclonal antibody product candidates and programs. The Company also announced the appointment of Henrik Rasmussen, M.D., Ph.D., of Nabi Biopharmaceuticals to its Medical Advisory Board.
Symphogen A/S får patent på Sympress™ teknologi til produktion af rekombinante polyklonale antistoffer
KØBENHAVN, Danmark, 11. september 2006.
Biotekvirksomheden Symphogen A/S meddeler, at det Europæiske Patent Kontor har udstedt patent (EP 1,538,830) på en metode til produktion af såkaldte rekombinante polyklonale antistoffer, som er en ny type lægemidler, der blandt andet kan bruges til behandling af infektioner og kræft.
Symphogen Issued Patent Covering Sympress™ Technology for Manufacturing Rekombinant Polyclonal Antibodies
COPENHAGEN, Denmark - September 11, 2006.
Symphogen announced today that the European Patent Office issued European Patent number 1,583,830 titled, "Method for manufacturing recombinant polyclonal proteins". The patent broadly covers Symphogen's proprietary method of manufacturing recombinant human polyclonal antibodies (pAb) with the Sympress™ manufacturing platform. In addition to covering Symphogen's proprietary gene technology for polyclonal antibody production, the patent also covers use of pAb manufacturing cell lines and Symphogen's polyclonal antibody expression libraries.
Symphogen to evaluate AttSite™ Recombinase for development of manufacturing cell lines
COPENHAGEN, Denmark - July 27, 2006.
RheoGene Inc., has granted a nonexclusive research license to Symphogen A/S of Copenhagen, Denmark, to use the Pennsylvania biotech company's gene-targeting AttSite™ recombinase, an enzyme-based technology designed to guide gene insertion into specific "hot spots" within the genome to ease the exchange of DNA and development of new genetic sequences and cell lines. Financial terms were not disclosed.
Symphogen appoints Dr Søren Bregenholt Vice President of Project Management
COPENHAGEN, Denmark - July 6, 2006.
With the appointment of Dr Søren Bregenholt, 35, as Vice President of Project Management Symphogen strengthens its position as a project-driven, research-based biotech company. The expansion of Symphogen and the many future project activities place great demands on a well-organised matrix organisation. Søren Bregenholt's participation in executive management is therefore a natural, strategic step toward reinforcing a well functioning and dynamic company.
Symphoen udnævner Søren Bregenholt til Vice President of Project Management
København, 6. juli 2006.
Med udnævnelsen af Dr. Søren Bregenholt, 35, til Vice President of Project Management styrker Symphogen A/S sin position som en projektdrevet, forskningsbaseret biotekvirksomhed. Symphogens ekspansion og mange fremtidige projektaktiviteter stiller store krav til en velorganiseret matrixorganisation. Sørens Bregenholts deltagelse i virksomhedens ledelse er derfor et naturligt, strategisk skridt i cementeringen af en velfungerende og dynamisk virksomhed.
Biovitrum and Symphogen Enter Co-development and Commercialization Agreement for Recombinant Polyclonal Antibodies for the treatment of certain blood disorders
Copenhagen, Denmark - February 1, 2006.
Symphogen A/S, Denmark and Biovitrum AB, Sweden have entered into a co-development and commercialization agreement for Sym001, Symphogen's lead product. Sym001 is a combination of 25 different recombinant anti-Rhesus D antibodies for the treatment of both Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic Disease of the Newborn (HND).
Symphogen på vej mod nyt lægemiddel
København, 1. februar 2006.
Den danske biotekvirksomhed Symphogen A/S tager nu et vigtigt forretningsmæssigt skridt og indgår sin første samarbejdsaftale omkring videreudvikling af virksomhedens første lægemiddel. Symphogen A/S og svenske Biovitrum meddeler i dag, at de har indgået en samarbejdsaftale, der sikrer en hurtig udvikling og markedsføring af Symphogens første lovende produkt, Sym001.
Kapitaltilførsel på 154 millioner kroner til Symphogen til videre udvikling af rekombinante polyklonale antistoffer
København, 8. januar 2006.
Biotekselskabet Symphogen A/S har fået tilført ny kapital fra nuværende og nye internationale investorer. Investorerne er blandt andet Lønmodtagernes Dyrtidsfond som investerer 56 mio kroner i denne runde, det amerikanske ventureselskab Essex Woodlands Health Ventures med 26 mio kroner og Novo A/S med samme beløb, samt Scandinavian Life Science med 12,5 mio kroner og VækstFonden med 19 mio kroner. Også Takeda Research Investments , som er investeringsarmen for Japans største medicinalvirksomhed Takeda, har ønsket at investere i Symphogen – med 15 mio kroner.
Symphogen A/S and Cambridge Antibody Technology Sign Patent Licensing Agreement
Copenhagen, Denmark - 23 August, 2005.
Symphogen A/S, a biotechnology company pioneering recombinant human polyclonal antibodies for the treatment and prevention of human disease, announced today that it has entered into a patent license agreement with Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG).
Symphogens Success in Manufacturing Consistent Batches of Polyclonal Antibodies for Clinical Trials Attracts New USD 25 Million Investment
Copenhagen, Denmark - November 2, 2004.
Symphogen A/S (the Company), the Danish biotech company pioneering recombinant natural human antibodies for the treatment and prevention of human disease, today announced the initial closing of a Series C financing round involving commitments from existing investors of USD 25 million. The investors, who are participating pro-rata, are Essex Woodlands Health Ventures (USA), Scandinavian Life Science (SLS) Venture, Novo A/S, LD Pensions and Vaekstfonden.